Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 juin 2016 07h00 HE | Source: Immunomedics, Inc.

Immunomedics to Present at Jefferies 2016 Global Healthcare Conference

MORRIS PLAINS, N.J., June 07, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Company will present at Jefferies 2016 Global Healthcare Conference at...
06 juin 2016 15h15 HE | Source: Immunomedics, Inc.

Immunomedics’ Sacituzumab Govitecan (IMMU-132) Demonstrates Efficacy and Safety in Non-Small-Cell Lung Cancer Patients With Multiple Prior Treatments, Including Immuno-Oncology

CHICAGO, June 06, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that sacituzumab govitecan (IMMU-132), its lead investigational antibody-drug conjugate (ADC), shrank...
06 juin 2016 07h00 HE | Source: Immunomedics, Inc.

Immunomedics Announces Sacituzumab Govitecan (IMMU-132) is Active in Patients With Previously-Treated Metastatic Small-Cell Lung Cancer

CHICAGO, June 06, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today reported an overall response rate of 24% (8/33) in assessable patients with metastatic small-cell lung cancer...
03 juin 2016 09h16 HE | Source: Immunomedics, Inc.

Immunomedics Provides Update on Triple-Negative Breast Cancer Presentation at ASCO

MORRIS PLAINS, N.J., June 03, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Company was advised late yesterday that its abstract, “Therapy of...
19 mai 2016 07h00 HE | Source: Immunomedics, Inc.

Immunomedics to Report Updated Results for Sacituzumab Govitecan (IMMU-132) in Breast and Lung Cancers at Clinical Science Symposia of 2016 ASCO Annual Meeting

MORRIS PLAINS, N.J., May 19, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Scientific Program Committee of the American Society of Clinical Oncology (ASCO)...
04 mai 2016 16h00 HE | Source: Immunomedics, Inc.

Immunomedics Announces Third Quarter Fiscal 2016 Results and Clinical Program Developments

MORRIS PLAINS, N.J., May 04, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today reported financial results for the third quarter ended March 31, 2016. The Company also highlighted...
02 mai 2016 12h16 HE | Source: Immunomedics, Inc.

Immunomedics Announces Abstract on Sacituzumab Govitecan (IMMU-132) in Patients With Triple-Negative Breast Cancer Selected for Best of ASCO Program

MORRIS PLAINS, N.J., May 02, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that the abstract on sacituzumab govitecan (IMMU-132), the Company’s lead antibody-drug...
29 avr. 2016 11h45 HE | Source: Immunomedics, Inc.

Immunomedics Reports Responses With Sacituzumab Govitecan (IMMU-132) in Patients With Metastatic Solid Cancers Who Failed Prior Checkpoint-Inhibitor Therapy

BOSTON, April 29, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced that objective durable responses have been achieved with sacituzumab govitecan, its lead antibody-drug...
28 avr. 2016 07h00 HE | Source: Immunomedics, Inc.

Immunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2016 Financial Results

MORRIS PLAINS, N.J., April 28, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that it will host a conference call and live audio webcast on Thursday, May 5, 2016 at...
22 avr. 2016 07h00 HE | Source: Immunomedics, Inc.

Immunomedics Appoints Dr. Sol J. Barer Special Advisor to the Chairman

MORRIS PLAINS, N.J., April 22, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced that Dr. Sol J. Barer has been appointed Special Advisor to the Chairman, and will work in...

Page précédente

Page suivante